Cefadroxil
General
- Type: First generation cephalosporin
- Dosage Forms: capsule, oral suspension, tablet
- Dosage Strengths: capsule: 500mg; oral suspension: 250mg/5mL, 500mg/5mL; tablet: 1g
- Routes of Administration: PO
- Common Trade Names: Duricef, Ultracef
Adult Dosing
Infections, bacterial
- 1-2g/day PO divided q12-24h
Pharyngitis/tonsillitis, streptococcal
- 1g PO divided q12-24h x 10days
Pediatric Dosing
Infections, bacterial
- 30mg/kg/day PO divided q12-24h max 2g/day
Pharyngitis/tonsillitis, streptococcal
- 30mg/kg/day PO divided q12-24h x 10days, max 1g/day
Special Populations
- Pregnancy Rating: B (no evidence of harm)
- Lactation: safe (no risk/minimal risk)
- Renal Dosing
- Adult
- GFR 25-50: 1g x1, then 500mg q12h
- GFR 10-25: 1g x1 then 500mg q24h
- GFR < 10: 1g x1, then 500mg q36h
- HD: give 0.5-1g supplement
- PD: 500mg q24h
- Pediatric
- GFR 10-25: give q24h
- GFR < 10: give q36h
- HD: give supplement
- PD: no supplement
- Adult
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- angioedema
- neutropenia
- thrombocytopenia
- pancytopenia
- anemia, hemolytic
- aplastic anemia
- hemorrhage
- seizures
- superinfection
- C.difficile-associated diarrhea
Common
- diarrhea
- nausea
- dyspepsia
- urticaria
- pruritus
- rash
- vomiting
- ALT, AST elevation
Pharmacology
- Half-life:
- 78-96 min, 20-25hr (ESRD)
- Metabolism:
- minimal, site unknown
- Excretion:
- urine primarily (>90% unchanged)
- Mechanism of Action:
- bacteriacidal; inhibits cell wall mucopeptide synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014